STROMUSC YK11 Bodybuilding CAS:1370003-76-1
YK11 is a synthetic compound often categorized as a SARM (Selective Androgen Receptor Modulator), but some sources suggest it might function more like a myostatin inhibitor. Myostatin is a protein that limits muscle growth, so inhibiting it can lead to increased muscle mass. However, I need to verify this. Is it a SARM or a myostatin inhibitor? Some research indicates that YK11 acts as a partial agonist of the androgen receptor, like SARMs, but also inhibits myostatin by interfering with its signaling pathway. This dual action might make it unique compared to other SARMs. I should highlight this in the features section. Next, features. YK11's main features would include its mechanism of action—both androgen receptor modulation and myostatin inhibition. It might have anabolic effects on muscle tissue while minimizing androgenic side effects, but since it's a partial agonist, there could still be some suppression of natural testosterone. Unlike typical SARMs, the myostatin inhibition aspect could lead to more significant muscle growth.
YK11 is a synthetic compound often misclassified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional SARMs, YK11 exhibits a dual mechanism: it acts as a partial agonist of the androgen receptor (AR) while inhibiting myostatin, a protein that limits muscle growth. This unique combination positions YK11 in a niche category, blending AR modulation with direct interference in muscle-regulatory pathways.
Key Features
Dual Mechanism:
●Androgen Receptor Agonism: Binds partially to ARs, promoting anabolic activity in muscle and bone with reduced androgenic effects on organs like the prostate.
●Myostatin Inhibition: Blocks myostatin signaling, preventing it from limiting muscle cell proliferation. This dual action may amplify hypertrophic effects beyond typical SARMs.
2.Tissue Selectivity: While not fully selective, YK11's partial agonism may spare some androgenic tissues, though its myostatin inhibition could lead to systemic muscle growth.
3.Research Status: Lacks clinical trials; data primarily derive from preclinical studies and anecdotal user reports.
Applications
●Bodybuilding: Leveraged for rapid muscle gain and fat loss due to enhanced protein synthesis and reduced myostatin activity.
●Medical Potential: Theoretical use in muscle-wasting conditions (e.g., cachexia, muscular dystrophy) by counteracting atrophy pathways.
●Scientific Research: Studied for myostatin's role in metabolism and fibrosis, offering insights into regenerative medicine.
Benefits
●Muscle Hypertrophy: Combined AR activation and myostatin blockade may yield superior gains compared to conventional SARMs.
●Fat Reduction: Enhanced metabolic rate from increased lean mass and potential direct lipid oxidation effects.
●Strength and Recovery: Users report improved strength and reduced recovery times, possibly due to myostatin's role in muscle repair.
Dosage and Cycle
●Anecdotal Dosage: 5–10 mg/day orally, often split into two doses to maintain stable blood levels.
●Cycle Length: Typically 8–12 weeks, though longer cycles risk pronounced suppression of natural testosterone.
●Stacking: Occasionally paired with SARMs (e.g., Ligandrol) or testosterone boosters to offset suppression.
Half-Life
Estimated Half-Life: ~12–24 hours, suggesting once or twice daily dosing. Absence of clinical data necessitates cautious titration.
Post-Cycle Therapy (PCT)
●Necessity: Likely required due to AR-mediated suppression of the HPTA axis. Severity varies with cycle length and dosage.
●Protocols: SERMs like Tamoxifen (20 mg/day) or Clomid (25–50 mg/day) for 3–4 weeks post-cycle to restore endogenous testosterone.
●Monitoring: Bloodwork (testosterone, LH, FSH) pre- and post-cycle to gauge recovery needs.
Risks and Side Effects
●Hormonal Suppression: Despite partial agonism, prolonged use can suppress natural testosterone, necessitating PCT.
●Joint and Tendon Stress: Unchecked muscle growth may strain connective tissues, increasing injury risk.
●Unknown Long-Term Effects: Myostatin's role in cardiac and smooth muscle health raises unanswered safety concerns.
Legal and Regulatory Status
●Non-Approved: Not FDA-approved; classified as a research chemical.
●Sports Bans: Prohibited by WADA and major athletic organizations due to potential performance enhancement.
Clinical Data
|
Brand |
STROMUSC |
|
Trade names |
YK11; (17α,20E)-17,20-diene-21-carboxylic acid methyl ester |
|
CAS |
1370003-76-1 |
|
Molar mass |
430.541 |
|
Formula |
C25H34O6 |
|
Purity |
Above 98% |
|
Apprarance |
5mg*30caps |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-19128233885
Conclusion
YK11's dual action offers intriguing possibilities for muscle growth and metabolic health but operates in a regulatory and scientific gray area. Its myostatin inhibition could revolutionize treatments for muscle atrophy, yet the lack of clinical evidence demands caution. Users should prioritize rigorous PCT and medical supervision to mitigate risks, acknowledging the compound's experimental nature.
Hot Tags: STROMUSC YK11 Bodybuilding CAS:1370003-76-1, China STROMUSC YK11 Bodybuilding CAS:1370003-76-1 manufacturers, suppliers, factory, RAD140 increase lean muscle mass, SR9011, SR9009, SR9009 Hormone and Metabolic Regulators, OTR-AC, MK2866 Treat Muscular Dystrophy and Osteoporosis
